Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Tiago Torres

Showing results (221-230 of 274) with videos related to

Pageof 28
Sort By:
American Journal of Clinical Dermatology|October 7, 2023
Guselkumab-Treated Patients with Plaque Psoriasis Who Achieved Complete Skin Clearance for ≥ 156 Consecutive Weeks: A Post-Hoc Analysis From the VOYAGE 1 Clinical TrialLuis Puig, Antonio Costanzo, Elke M G J de Jong, et al.
Biodrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy|October 1, 2025
Risankizumab in Patients with Psoriasis with Current or Previous Malignancy: A Multicenter, Retrospective Real-World StudyMarco Sousa, Ana Luísa João, Martim Luz, et al.
The Journal of Dermatological Treatment|May 6, 2026
Complete clearance of high-impact sites with risankizumab in patients with psoriasis: a 2-year real-world retrospective multicenter cohort studyMargarida Contente, Ana Luísa João, Martim Luz, et al.
Clinical and Experimental Dermatology|May 24, 2025
Outcomes of Psoriasis Area and Severity Index (PASI) and PASI components in two phase III trials of deucravacitinib in patients with moderate to severe plaque psoriasisMark Lebwohl, Melinda J Gooderham, Richard B Warren, et al.
Acta Medica Portuguesa|January 7, 2017
Portuguese Position Paper on the Use of Biosimilars in PsoriasisTiago Torres, Ana Ferreira, Paulo Ferreira, et al.
Drugs in Context|June 28, 2021
Dermatologists' attitude towards psoriasis treatment during the COVID-19 pandemicTiago Torres, Marta Pereira, Maria João Paiva Lopes, et al.
Dermatology and Therapy|April 26, 2025
Multidimensional Burden of Moderate-to-Severe Atopic Dermatitis in Adolescent and Adult Patients from Portugal and Greece: Results from the Global Cross-Sectional Study MEASURE-ADPedro Mendes-Bastos, Elisavet Lazaridou, Tiago Torres, et al.
Clinical and Translational Allergy|April 13, 2024
Dilemmas of nomenclature: Web search analysis reveals European preferences in atopic skin diseasesHannah Wecker, Stefanie Ziehfreund, Sebastian Sitaru, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|April 20, 2024
Burden of atopic dermatitis in Europe: A population-centred approach leveraging web search data in 21 European countriesHannah Wecker, Stefanie Ziehfreund, Sebastian Sitaru, et al.
The British Journal of Dermatology|June 28, 2025
Efficacy and Safety of Upadacitinib Dose Escalation and Reduction in Adult Patients With Moderate-To-Severe Atopic Dermatitis: Results of a Randomized, Blinded, Treat-To-Target, Multicenter Phase 3b/4 Study (Flex Up)Melinda Gooderham, Tiago Torres, Shinichi Imafuku, et al.
Pageof 28

Showing results (221-230 of 274) with videos related to

Sort By:
Pageof 28
American Journal of Clinical Dermatology|October 7, 2023
Guselkumab-Treated Patients with Plaque Psoriasis Who Achieved Complete Skin Clearance for ≥ 156 Consecutive Weeks: A Post-Hoc Analysis From the VOYAGE 1 Clinical TrialLuis Puig, Antonio Costanzo, Elke M G J de Jong, et al.
Biodrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy|October 1, 2025
Risankizumab in Patients with Psoriasis with Current or Previous Malignancy: A Multicenter, Retrospective Real-World StudyMarco Sousa, Ana Luísa João, Martim Luz, et al.
The Journal of Dermatological Treatment|May 6, 2026
Complete clearance of high-impact sites with risankizumab in patients with psoriasis: a 2-year real-world retrospective multicenter cohort studyMargarida Contente, Ana Luísa João, Martim Luz, et al.
Clinical and Experimental Dermatology|May 24, 2025
Outcomes of Psoriasis Area and Severity Index (PASI) and PASI components in two phase III trials of deucravacitinib in patients with moderate to severe plaque psoriasisMark Lebwohl, Melinda J Gooderham, Richard B Warren, et al.
Acta Medica Portuguesa|January 7, 2017
Portuguese Position Paper on the Use of Biosimilars in PsoriasisTiago Torres, Ana Ferreira, Paulo Ferreira, et al.
Drugs in Context|June 28, 2021
Dermatologists' attitude towards psoriasis treatment during the COVID-19 pandemicTiago Torres, Marta Pereira, Maria João Paiva Lopes, et al.
Dermatology and Therapy|April 26, 2025
Multidimensional Burden of Moderate-to-Severe Atopic Dermatitis in Adolescent and Adult Patients from Portugal and Greece: Results from the Global Cross-Sectional Study MEASURE-ADPedro Mendes-Bastos, Elisavet Lazaridou, Tiago Torres, et al.
Clinical and Translational Allergy|April 13, 2024
Dilemmas of nomenclature: Web search analysis reveals European preferences in atopic skin diseasesHannah Wecker, Stefanie Ziehfreund, Sebastian Sitaru, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|April 20, 2024
Burden of atopic dermatitis in Europe: A population-centred approach leveraging web search data in 21 European countriesHannah Wecker, Stefanie Ziehfreund, Sebastian Sitaru, et al.
The British Journal of Dermatology|June 28, 2025
Efficacy and Safety of Upadacitinib Dose Escalation and Reduction in Adult Patients With Moderate-To-Severe Atopic Dermatitis: Results of a Randomized, Blinded, Treat-To-Target, Multicenter Phase 3b/4 Study (Flex Up)Melinda Gooderham, Tiago Torres, Shinichi Imafuku, et al.
Pageof 28